NDA 211843 · Mission Pharmacal
Thiola Ec
Tiopronin · Oral · Reducing and Complexing Thiol
OrphanLast checked: Nov 20, 2026Latest source record: Mar 8, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2019
Jun 28, 2019
Approved uses
1
Original approval plus efficacy supplements
Registered trials
4
0 Phase 3, 0 recruiting
FAERS reports
900
341 serious, 53 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 7, 2025.
THIOLA EC is indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. THIOLA EC is a reducing and complexing thiol indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 20 kg and greater with severe homozygous cystinuria, who are not responsive to these measures alone. ( 1 )
Mechanism: The goal of therapy is to reduce urinary cystine concentration below its solubility limit. Tiopronin is an active reducing agent which undergoes thiol-disulfide exchange with cystine to form a mixed disulfide of tiopronin-cysteine. From this reaction, a water-soluble mixed disulfide is formed and the amount of sparingly soluble cystine is reduced.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
2 products under this application
- THIOLA EC · TIOPRONIN 100MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
- THIOLA EC · TIOPRONIN 300MG · TABLET, DELAYED RELEASE, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Tiopronin" as an intervention, any sponsor and status, largest first.
- Efficacy and Safety Study of Magnesium Isoglycyrrhizinate Injection in Subjects With Acute Drug-induced Liver InjuryPivotal-lookingCompleted
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
NCT02734966 · 174 participants · Start Dec 2007 · Primary completion Dec 2008
Drug: Magnesium Isoglycyrrhizinate Injection 100mg OD; Magnesium Isoglycyrrhizinate Injection 200mg OD and 1 more · For: Drug-Induced Liver Injury
Sites: Beijing, China; Nanjing, China; Shanghai, China · 8 sites in all
E. Sander ConnollyAcademic, hospital or other
NCT01095731 · 60 participants · Start Apr 2010 · Primary completion Jul 2012
Drug: Tiopronin; Placebo · For: Aneurysmal Subarachnoid Hemorrhage
Sites: Gainesville, Florida; New York, New York; Seattle, Washington
NYU Langone HealthAcademic, hospital or other
NCT02125721 · 10 participants · Start Jun 2012 · Primary completion Dec 2017
Drug: Tiopronin 1g per day; Tiopronin 2g per day and 1 more · For: Cystinuria
Sites: New York, New York
NYU Langone HealthAcademic, hospital or other
NCT03663855 · 10 participants · Start Nov 1, 2018 · Primary completion Sep 10, 2019
Drug: Tiopronin · For: Cystinuria
Sites: New York, New York
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective286
- fatigue49
- pyrexia48
- rash48
- nausea45
- product dose omission issue36
- vomiting30
- flank pain26
- proteinuria26
- urinary tract infection26
- diarrhoea23
- dyspepsia21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 2 |
| 2005 | 4 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 6 |
| 2011 | 33 |
| 2012 | 34 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 7 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 23 |
| 2020 | 36 |
| 2021 | 64 |
| 2022 | 134 |
| 2023 | 132 |
| 2024 | 147 |
| 2025 | 181 |
| 2026 | 86 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Thiola EC (Tiopronin)
2024 spending
$26.6M
Beneficiaries
285
3,028 claims
Per beneficiary
$93,242
$75.85 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,792,840 |
| 2021 | $21,278,094 |
| 2022 | $21,868,127 |
| 2023 | $23,230,085 |
| 2024 | $26,573,882 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Cystinuria: clinical practice recommendation.
Servais A, Thomas K, Dello Strologo L, et al. · Kidney Int 2021 · Research Support, Non-U.S. Gov't, Systematic Review
- Pharmacological interventions for the management of cystinuria: a systematic review.
Bhatt NP, Deshpande AV, Starkey MR · J Nephrol 2024 · Systematic Review
- Influence of Tiopronin on the Metabolism of Alcohol in Healthy Subjects.
Nass F, Schneider B, Wilm S, et al. · Drug Res (Stuttg) 2017 · Randomized Controlled Trial
- Clinical course and cystine stone formation during tiopronin treatment.
Lindell A, Denneberg T, Hellgren E, et al. · Urol Res 1995 · Clinical Trial, Research Support, Non-U.S. Gov't
- Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials.
Niu H, Sanabria-Cabrera J, Alvarez-Alvarez I, et al. · Pharmacol Res 2021 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Effect of increasing doses of cystine-binding thiol drugs on cystine capacity in patients with cystinuria.
Malieckal DA, Modersitzki F, Mara K, et al. · Urolithiasis 2019 · Randomized Controlled Trial
Sponsor: Mission Pharmacal
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.